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Clopidogrel–Drug Interactions
Eric R. Bates, MD,* Wei C. Lau, MD,† Dominick J. Angiolillo, MD, PHD‡
Ann Arbor, Michigan; and Jacksonville, Florida
Multidrug therapy increases the risk for drug–drug interactions. Clopidogrel, a prodrug, requires hepatic cytochrome
P450 (CYP) metabolic activation to produce the active metabolite that inhibits the platelet P2Y12 adenosine diphos-
phate (ADP) receptor, decreasing platelet activation and aggregation processes. Atorvastatin, omeprazole, and sev-
eral other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel,
reducing clopidogrel responsiveness. Conversely, other agents increase clopidogrel responsiveness by inducing CYP
activity. The clinical implications of these pharmacodynamic interactions have raised concern because many of these
drugs are coadministered to patients with coronary artery disease. There are multiple challenges in proving that a
pharmacodynamic drug–drug interaction is clinically significant. To date, there is no consistent evidence that clopi-
dogrel–drug interactions impact adverse cardiovascular events. Statins and proton pump inhibitors have been shown
to decrease adverse clinical event rates and should not be withheld from patients with appropriate indications for
therapy because of concern about potential clopidogrel–drug interactions. Clinicians concerned about clopidogrel–
drug interactions have the option of prescribing either an alternative platelet P2Y12 receptor inhibitor without
known drug interactions, or statin and gastro-protective agents that do not interfere with clopidogrel metabolism.
(J Am Coll Cardiol 2011;57:1251–63) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.024r
PDual antiplatelet therapy with aspirin and clopidogrel is
recommended treatment for percutaneous coronary inter-
vention (PCI) (1) and acute coronary syndromes (ACS)
(2,3). Whereas multidrug therapy with antiplatelet drugs,
lipid-lowering and glucose-lowering agents, antihyperten-
sive drugs, and even antidepressants has been suggested as a
therapeutic strategy to reduce cardiovascular risk, multiple
drug prescriptions increase the risk for drug–drug inter-
actions. This is particularly true if more than 1 agent
requires significant hepatic metabolism (4). Clopidogrel,
atorvastatin, omeprazole, and many other drugs require
hepatic cytochrome P450 (CYP) metabolism. Importantly,
clopidogrel–atorvastatin (5) and clopidogrel–omeprazole (6)
drug interactions have been described that limit the ability of
clopidogrel to inhibit platelet activation and aggregation pro-
cesses. The clinical implications of these pharmacodynamic
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2010; accepted November 19, 2010.interactions have raised concern because many of these drugs
are concomitantly administered to patients with coronary
artery disease (7,8). The purpose of this review is to summarize
the pharmacodynamic and clinical evidence regarding these
drug interactions and other clopidogrel–drug interactions.
Drug Metabolism
The most important metabolic pathway for most medications
involves oxidation by 1 or more CYP isoenzymes. These
isoenzymes are generally most highly expressed in hepatocytes,
but are also present in other tissues including the intestines and
skin. As oxidative metabolism is the first step in the clearance
of many drugs, CYP isoenzymes are central to many clinically
relevant drug–drug interactions. The activity of CYP isoen-
zymes may also be a necessary step for conversion of a prodrug
to a clinically beneficial active metabolite.
Clopidogrel bisulfate, an inactive thienopyridine prodrug,
is 85% hydrolyzed in vivo by esterases to an inactive
carboxylic acid derivative (Fig. 1). The remaining drug
undergoes oxidative biotransformation to its active thiol
metabolite by a 2-step, CYP-dependent process in which
CYP3A4/5 and CYP2C19 have the greatest roles, with
lesser involvement from CYP2B6, CYP1A2, and CYP2C9
(9). The active metabolite then irreversibly inhibits the
platelet P2Y12 adenosine diphosphate (ADP) receptor by
forming an inactivating disulfide bond with cysteine on the
P2Y12 receptor (10). This blocks ADP from binding to the
eceptor and stimulating platelet activation and aggregation.
hysical and genetic factors that induce, inhibit, or competeor CYP activity can modulate biotransformation of clopi-
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and result in interindividual vari-
ability of clopidogrel responsive-
ness. For instance, the degree of
CYP3A4 metabolic activity is in-
versely related to the antiplatelet
effects of clopidogrel (11).
CYP2C19 polymorphisms asso-
ciated with enzymatic activity
also impact clopidogrel metabo-
lism and responsiveness (12).
Statins act by inhibiting 3-
hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase,
the rate-limiting enzyme of cho-
lesterol synthesis in the liver.
CYP3A4 is important for the
elimination of lipophilic statins
(lovastatin, simvastatin, and ator-
vastatin), but hydrophilic statins
(fluvastatin, pravastatin, and rosuvastatin) are not significantly
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
cAMP  cyclic adenosine
monophosphate
CYP  cytochrome P450
H2RA  histamine2
receptor antagonist
HMG-CoA  3-hydroxy-3-
methylglutaryl coenzyme A
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PPI  proton pump
inhibitor
VASP  vasodilator-
stimulated phosphoprotein
Figure 1 Clopidogrel–Drug Interactions
After ingestion and absorption, 85% of clopidogrel bisulfate is hydrolyzed by estera
2-step process by hepatic P450 cytochromes. Multiple pharmacodynamic drug inte
phosphate; PPI  proton pump inhibitor.metabolized by this isoenzyme. Atorvastatin is the most
commonly prescribed statin, and its extensive hepatic metab-
olism has the potential to result in significant interactions with
other drugs (13). Atorvastatin calcium is initially converted to
the acid and lactone metabolites of the parent drug. Whereas
the acid form inhibits HMG-CoA reductase, the dominant
pathway of elimination is through the lactone form that binds
more tightly to CYP3A4 than many other substrates and
competes with a large number of medications, including
itraconazole, nelfinavir, ritonavir, cyclosporine, fibrates, eryth-
romycin, amiodarone, verapamil, fluoxetine, and nefazadone,
as well as grapefruit juice.
Proton pump inhibitors (PPIs) are prodrugs that are
activated in gastric parietal cells. PPIs irreversibly inhibit the
gastric H/K ATPase (the proton pump) that accom-
lishes the final step in acid secretion. Omeprazole, the
ost widely used PPI, is metabolized to hydroxyomeprazole
nd omeprazole sulphate primarily by CYP2C19 and
YP3A4 (14). Omeprazole has a greater affinity for
YP2C19 than CYP3A4, compared with the other PPIs
hat are also metabolized by these isoenzymes, and therefore
an inactive carboxylic acid metabolite and the remaining drug is oxidized in a
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ractio
l
m
c
P
T
s
C
w
n
d
b
i
p
s
a
m
C
u
i
r
o
a
a
w
e
w
w
c
a
d
m
a
i
p
r
a
v
c
p
a
b
T
i
c
s
n
s
c
m
d
s
n
N
s
p
a
i
P
t
a
S
i
o
o
h
d
R
n
(
m
c
t
a
o
(
T
P
E
t
d
c
t
a
e
(
1253JACC Vol. 57, No. 11, 2011 Bates et al.
March 15, 2011:1251–63 Clopidogrel–Drug Interactionshas a greater potential for drug–drug interactions mediated
by CYP2C19. Omeprazole has been shown to reduce the
clearance of diazepam, phenytoin, and warfarin. Conversely,
ketaconazole and clarithromycin have a high affinity for
CYP3A4 and increase omeprazole concentrations. Another
mechanism by which omeprazole may induce drug interac-
tions is by elevating gastric pH and altering drug absorption
rates.
Due to their common requirement for CYP3A4 metab-
olism, a clopidogrel–atorvastatin interaction may exist. Sim-
ilarly, due to their common requirement for CYP2C19
metabolism, a clopidogrel–omeprazole interaction may ex-
ist. These interactions could result in competitive inhibition
decreasing the conversion of the clopidogrel prodrug to the
active metabolite and could potentially translate into an
increased risk for cardiovascular events because of inade-
quate platelet P2Y12 receptor inhibition. This is a particu-
arly important issue since many patients receiving treat-
ent to prevent recurrent cardiovascular events are suitable
andidates for all 3 drugs.
harmacodynamic Studies
he clopidogrel–atorvastatin interaction. We initially
urmised that clopidogrel was metabolized in humans by
YP3A4, not CYP1A2 as described in the rat (15), when
e serendipitously noted that patients on atorvastatin were
ot achieving the expected platelet inhibition with a clopi-
ogrel 300-mg loading dose (5), an observation confirmed
y Neubauer et al. (16). Responding to criticism that our
nitial study was observational and used a point-of-care
latelet aggregometer, we subsequently performed a pro-
pective randomized trial with standard light transmission
ggregometry and demonstrated an interaction with a 300-
g, but not a 600-mg, clopidogrel loading dose (17).
onsistent with these findings, results from an in vitro study
sing human microsomes containing single CYP isozymes
ndicated that both CYP3A4 and CYP3A5 were primarily
esponsible for oxidation of clopidogrel to its active metab-
lite. Exposure of human microsomes to clopidogrel and
torvastatin lactone at equimolar concentrations resulted in
90% inhibition of clopidogrel metabolism (18).
However, other studies (Table 1) have shown no impact
ith clopidogrel and atorvastatin coadministration (19–22),
specially when a higher clopidogrel loading dose (600 mg)
as tested (23–26), when measurements were made several
eeks later (21,27-29), or when atorvastatin was added to
lopidogrel (31–32). Limitations of the ex vivo platelet
ggregation studies include small sample sizes, different
rug doses, heterogeneous patient populations on multiple
edications, and differences in measurement techniques
nd protocols. Moreover, it is unknown how the variability
n clopidogrel metabolism due to CYP2C19 polymor-
hisms and CYP3A4 expression might have impacted the
esults. Expression of CYP3A4 varies 40-fold in humans,nd metabolism of CYP3A4 substrates varies 10-fold in
ivo (33).
In summary, no one disputes our initial finding that
lopidogrel is metabolized by CYP3A4, recognized by
latelet aggregometry because of a presumed clopidogrel–
torvastatin interaction, but many other reports have not
een able to confirm this interaction for various reasons.
he clopidogrel– omeprazole interaction. Gilard et al. (6)
nitially observed an association between PPI use and poor
lopidogrel response (Table 2). They subsequently demon-
trated that more patients on omeprazole than placebo were
onresponders after clopidogrel administration (34). Cuis-
et et al. (35) found more nonresponders on omeprazole
ompared with pantoprazole despite a high clopidogrel
aintenance dose of 150 mg/day. Sibbing et al. (36)
emonstrated less platelet inhibition and more nonre-
ponders in patients taking omeprazole compared with
on-PPI users or those given esomeprazole or pantoprazole.
eubauer et al. (37) also found more clopidogrel nonre-
ponders with omeprazole, but no interaction with panto-
razole. Staggering the administration times of clopidogrel
nd omeprazole does not decrease the interaction (38).
O’Donoghue et al. (39) measured decreased platelet
nhibition after a clopidogrel loading dose in patients taking
PIs. Likewise, Zuern et al. (40) noted less platelet inhibi-
ion in patients on PPIs, but no difference between agents,
lthough only 36 of 1,425 patients were given omeprazole.
ibbing et al. (36) and Siller-Matula et al. (41) found no
mpairment of clopidogrel responsiveness with pantoprazole
r esomeprazole. Similarly, Small et al. (42) described no
verall impact of coadministration with lansoprazole in 24
ealthy volunteers, although there was decreased clopi-
ogrel responsiveness in 8 high clopidogrel responders.
ecently, Angiolillo et al. (43) confirmed a pharmacoki-
etic/pharmacodynamic interaction between clopidogrel
administered at both standard and double loading/
aintenance dose regimens) and omeprazole (administered
oncomitantly or staggered), but found no interaction be-
ween clopidogrel and pantoprazole.
In summary, omeprazole has consistently been shown to
ttenuate clopidogrel responsiveness (34-38,43), whereas no
r limited interaction has been shown with pantoprazole
35–37,41,43) and other PPIs.
he SPICE (Evaluation of the Influence of Statins and
roton Pump Inhibitors on Clopidogrel Antiplatelet
ffects) trial. The SPICE trial (44) is enrolling 320 pa-
ients treated with dual antiplatelet therapy for at least 60
ays after bare-metal stent implantation. Patients will re-
eive either atorvastatin 80 mg or the comparator rosuvas-
atin 20 mg daily for 12 months. After 1 month, they will
lso receive either omeprazole 20 mg, pantoprazole 40 mg,
someprazole 40 mg, or the histamine2-receptor antagonist
H2RA) comparator ranitidine 300 mg daily for 11 months.
Percentage change in residual platelet aggregation by light
transmittance aggregometry and percentage change in
platelet reactivity index by flow cytometry will be measured
Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving AtorvastatinTable 1 Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving Atorvastatin
First Author (Ref. #)
(Year) Population Clopidogrel Dose Atorvastatin Dose Main Outcome Comment
Lau et al. (5)
(2003)
19 pts, 16 controls
undergoing PCI
300 mg 10–40 mg/day Atorvastatin dose-related decrease
of platelet aggregation
inhibition by clopidogrel at 24 h
First demonstration that clopidogrel
is activated by CYP3A4
Neubauer et al. (16)
(2003)
17 pts, 22 controls
undergoing PCI
300 mg then
75 mg/day
20–40 mg/day Dose-related decrease of platelet
aggregation inhibition by
atorvastatin at 5 and 48 h
Diminished interaction at 48 h
compared with 5 h
Muller et al. (23)
(2003)
7 pts, 12 controls undergoing
angiography
600 mg 20 mg/day No inhibition of platelet
aggregation at 2–4 h
No inhibition with high clopidogrel
loading dose
Mitsios et al. (27)
(2004)
13 pts, 8 controls with ACS 375 mg then
75 mg/day
10 mg/day No inhibition of platelet
aggregation at 5 weeks
No inhibition with sustained
coadministration
Piorkowski et al. (19)
(2004)
17 volunteers, 15 pts with
CAD, 17 controls
300 mg then
75 mg/day
20 mg/day No inhibition of platelet
aggregation at 4, 24, and 96 h
No inhibition with standard
clopidogrel loading dose
Serebruany et al. (20)
(2004)
25 pts, 25 controls
undergoing PCI
300 mg 10–40 mg/day No inhibition of platelet
aggregation at 24 h
No inhibition with standard
clopidogrel loading dose
Gorchakova et al. (24)
(2004)
58 pts, 90 controls
undergoing PCI
600 mg 10–40 mg/day No inhibition of platelet
aggregation at 2 h
No inhibition with high clopidogrel
loading dose
Smith et al. (21)
(2004)
20 pts, 5 controls
undergoing PCI
300 mg then
75 mg/day
Not stated No inhibition of platelet
aggregation at 4 h, 10 days,
and 28 days
No inhibition with standard
clopidogrel loading dose and
sustained coadministration
Mitsios et al. (28)
(2005)
26 pts, 25 controls
undergoing PCI for ACS
375 mg then
75 mg/day
20 mg/day No inhibition of platelet
aggregation at 5 weeks
No inhibition with sustained
coadministration
Lau et al. (17)
(2005)
36 volunteers, 24 controls 300, 450, 600 mg 40 mg/day Dose related decrease of platelet
inhibition by atorvastatin at
2, 4, 6, and 8 h
Inhibition with 300 mg, less
inhibition with 450 mg,
no inhibition with 600 mg
Trenk et al. (25)
(2008)
255 pts, 682 controls
undergoing angiography
600 mg Not stated No inhibition of platelet
aggregation at 2 h
No inhibition with high clopidogrel
loading dose
Geisler et al. (26)
(2008)
262 pts, 142 controls
undergoing PCI
600 mg Not stated No inhibition of platelet
aggregation at 6 h
No inhibition with high clopidogrel
loading dose
Farid et al. (22)
(2008)
31 volunteers 300 mg 80 mg/day No inhibition of platelet
aggregation at 2–24 h
No inhibition with standard
clopidogrel loading dose
Malmstrom et al. (29)
(2009)
22 pts with CAD 75 mg/day 20–80 mg/day No inhibition of platelet
aggregation at 2 weeks
No inhibition with sustained
coadministration
ACS  acute coronary syndrome; CAD  coronary artery disease; PCI  percutaneous coronary intervention; pts  patients.
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Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving Proton Pump InhibitorsTable 2 Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving Proton Pump Inhibitors
First Author (Ref. #)
(Year) Design Population End Point
Clopidogrel
Dose n Main Outcome Comments
Gilard et al. (6)
(2006)
Cohort High-risk PCI VASP (PRI) 300 mg then
75 mg/day
No PPI: 81
PPI: 24
No PPI: 49.5%
PPI: 61.4%
p  0.007
PPI decreased platelet inhibition
Gilard et al. (34)
(2008)
Prospective, Double-blind
RCT
Elective coronary stent
implantation
VASP (PRI) at 7 day 300 mg then
75 mg/day
Placebo: 60
Omeprazole: 64
Placebo: 39.8%
Omeprazole: 51.4%
p  0.0001
Omeprazole decreased platelet
inhibition
Cuisett et al. (35)
(2009)
Prospective RCT PCI for ACS VASP (PRI) at 1 month 600 mg then
150 mg/day
Pantoprazole: 52
Omeprazole: 52
Pantoprazole: 36%
Omeprazole: 48%
p  0.007
Omeprazole decreased platelet
inhibition vs. pantoprazole
Sibbing et al. (36)
(2009)
Cohort Prior coronary stent
implantation
Platelet aggregation 75 mg/day No PPI: 732
Esomeprazole: 42
Pantoprazole: 162
Omeprazole: 64
No PPI: 220 AUmin
Esomeprazole: 209 AUmin
Pantoprazole: 226 AUmin
Omeprazole: 296 AUmin
p  0.001 vs. omeprazole
Omeprazole decreased platelet
inhibition; esomeprazole and
pantoprazole did not
decrease platelet inhibition
Siller-Matula et al. (41)
(2009)
Cohort Undergoing PCI VASP (PRI) after PCI 600 mg then
75 mg/day
No PPI: 74
Esomeprazole: 74
Pantoprazole: 152
No PPI: 49%
Esomeprazole: 54%
Pantoprazole: 50%
Esomeprazole and pantoprazole
did not decrease platelet
inhibition
O’Donoghue et al. (39)
(2009)
Retrospective RCT cohort ACS with planned PCI Inhibition of platelet
aggregation at 6 h
600 mg then
150 mg/day
No PPI: 71
PPI: 28
No PPI: 35.2%
PPI: 23.2%
p  0.02
PPI decreased platelet inhibition
Zuern et al. (40)
(2009)
Cohort Undergoing PCI Platelet aggregation
at 20 h
600 mg then
75 mg/day
No PPI: 1,001
Esomeprazole: 108
Pantoprazole: 280
Omeprazole: 36
No PPI: 29.8%
PPI: 34%
p  0.001
PPI decreased platelet inhibition
Neubauer et al. (37)
(2010)
Cohort Undergoing PCI Platelet aggregation
at 48 h
600 mg then
75 mg/day
No PPI: 188
Esomeprazole or
omeprazole: 26
Pantoprazole: 122
No PPI: 2.75 
Esomeprazole or
omeprazole: 3.00 
Pantoprazole: 2.33 
Nonresponders: no PPI, 21.9%,
esomeprazole or omeprazole,
30.8%, pantoprazole, 16.4%.
AU  aggregation unit; PPI  proton pump inhibitor; PRI  platelet reactivity index; RCT  randomized clinical trial; VASP  vasodilator-stimulated phosphoprotein; other abbreviations as in Table 1.
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Clopidogrel–Drug Interactions March 15, 2011:1251–63at 30 and 60 days. Death, myocardial infarction (MI),
ischemia-driven repeat revascularization, stroke, gastroin-
testinal bleeding, and peptic ulcer disease will be docu-
mented at 30 days, 60 days, and 1 year. Unfortunately, this
protocol will not evaluate the interaction we described when
a loading dose of clopidogrel is given to a patient on chronic
atorvastatin therapy, nor will it measure the early potential
interaction between omeprazole and clopidogrel.
Clinical Studies
The clopidogrel–atorvastatin interaction. REGISTRY REPORTS.
The MITRA-Plus (Maximal Individual Therapy of Acute
Myocardial Infarction PLUS) registry (45) reported no
significant difference in mortality in 2,086 patients who
received clopidogrel for ACS with atorvastatin versus other
statins (3.2% atorvastatin, 2.7% other statins) (Table 3). A
registry report (46) from Nova Scotia including 1,537
patients with PCI found no significant difference in death,
MI, or unstable angina rates (4.6% atorvastatin, 3.5%
pravastatin). A single-center study (47) with 211 patients
undergoing coronary stenting receiving pretreatment with
clopidogrel described a lower rate of periprocedural MI for
patients on pravastatin and fluvastatin compared with ator-
vastatin and simvastatin. A single-center registry (48) found
benefit with the combination of statin therapy and clopi-
dogrel in patients with ACS that was not influenced by
statin choice. Two German single-center registries (25,26)
of patients undergoing coronary artery stenting found no
significant difference in clinical outcomes when clopidogrel
600 mg was initiated in patients on statin therapy. A report
from the GRACE (Global Registry of Acute Coronary
Events) (49) did not analyze differences between statins, so
did not address the possibility of an atorvastatin–clopidogrel
interaction.
ADMINISTRATIVE DATABASE REPORTS. Brophy et al. (50)
reported on 2,927 consecutive patients discharged after PCI
on clopidogrel and found a significantly increased risk for
the 30-day composite outcome of death, MI, unstable
angina, cerebrovascular events, and repeat revascularization
for those treated with atorvastatin (4.54% vs. 3.0%). Risk
was also increased with other prescriptions for drugs inhib-
iting CYP3A4 enzyme activity (odds ratio [OR]: 1.56, 95%
confidence interval [CI]: 1.02 to 2.37) and for those who
delayed filling the clopidogrel prescription. A subsequent
report (51) on 10,491 patients, with a different reference
group (nonstatin users) and 62-day follow-up, found no
significant risk for adverse outcomes with CYP-metabolized
statins compared with non–CYP-metabolized statins, but
could not exclude a small risk (hazard ratio [HR]: 1.16; 95%
CI: 0.91 to 1.47).
POST HOC RANDOMIZED CLINICAL TRIAL REPORTS. A re-
ort from the CREDO (Clopidogrel for the Reduction of
vents During Observation) trial (52) concluded that there
as no statistically significant interaction on the 1-year Cl
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March 15, 2011:1251–63 Clopidogrel–Drug Interactionscomposite end point of death, MI, and stroke with clopi-
dogrel and statin coadministration (7.6% CYP3A4 statins,
5.4% non-CYP3A4 statins) or atorvastatin (6.5% atorvasta-
tin, 4.6% pravastatin). Similar findings were found in a post
hoc analysis of the CHARISMA (Clopidogrel for High
Atherothrombotic Risk and Ischemic Stabilization, Man-
agement, and Avoidance) trial (5.9% CYP3A4 statins, 5.7%
non-CYP3A4 statins; 5.7% atorvastatin, 5.1% pravastatin)
(53). A post hoc analysis from the PROVE IT–TIMI 22
(Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy–Thrombolysis In Myocardial Infarction 22) trial (54)
addressed a different question and found no impact of
adding atorvastatin to patients already on clopidogrel.
In summary, increased risk was seen in 2 studies (47,50),
but not in 3 studies (25,26,48), 2 of which used a high
clopidogrel loading dose (25,26). In other studies, there was
an insignificant trend for worse outcomes with atorvastatin
compared with pravastatin or no statin (45,46,52,53) and
with CYP-metabolized statins compared with non–CYP-
metabolized statins (51–53), but no consistent signal for
increased cardiovascular risk with drug coadministration.
The clopidogrel–omeprazole interaction. REGISTRY REPORTS.
A letter to the editor first suggested that PPI exposure
increased the rate of MI in patients on clopidogrel (55).
Two small (56,57) and 1 large (58) single-center reports
supported increased adverse cardiac events in patients dis-
charged on a PPI after PCI. Conversely, omeprazole and
other PPIs had no effect on the clinical response to
clopidogrel in the FAST-MI (French Registry of Acute
ST-Elevation and Non–ST-Elevation Myocardial Infarc-
tion) registry that enrolled 2,208 patients with MI and
assessed 1-year risk for death, MI, and stroke (59).
ADMINISTRATIVE DATABASE REPORTS. Ho et al. (60) stud-
ied 8,205 veterans discharged after hospitalization for ACS
and found an increased risk for mortality or rehospitaliza-
tion for ACS for patients treated with clopidogrel plus PPI
compared with clopidogrel without PPI (OR: 1.25, 95% CI:
1.11 to 1.41). The increased risk was present in patients
taking omeprazole (Table 4). Similarly, Juurlink et al. (61)
conducted a nested case-control study including 782 elderly
Canadian patients readmitted to the hospital for recurrent
MI within 90 days following hospital discharge for MI, of
whom 46 were taking pantoprazole and 148 were taking
omeprazole, lansoprazole, or rabeprazole. Risk was in-
creased with PPI use (OR: 1.27, 95% CI: 1.03 to 1.57), but
not with pantoprazole or H2RAs. Kreutz et al. (62) studied
6,690 patients with commercial insurance in the Medco
ealth Solutions, Inc. (Franklin Lakes, New Jersey) data-
ase after coronary stent implantation and described an
ncreased 1-year risk for the composite outcome of hospi-
alization for cardiovascular death, ACS, cerebrovascular
vent, or revascularization in patients prescribed a PPI (HR:
.51, 95% CI: 1.39 to 1.64). Risk was increased for all PPIs,
ut not with H2RAs. Huang et al. (63) also noted an
ncreased risk of rehospitalization and death in East Asian 0atients prescribed PPIs after PCI. Stockl et al. (64)
ttempted to address some of the limitations of performing
n administrative claims–based analysis by using propensity
coring, but the results illustrate the analytical challenges.
he negative impact of PPIs on risk (HR: 1.93, 95% CI:
.05 to 3.54) was greater than the incremental benefit of
dding clopidogrel to aspirin in any randomized clinical
rial, and risk was demonstrated with pantoprazole (HR:
.91, 95% CI: 1.19 to 3.06), despite no prior pharmacody-
amic evidence of a clopidogrel–pantoprazole interaction.
Rassen et al. (65) noted low event rates in 18,565 elderly
atients with ACS or PCI followed for MI hospitalization
r death. The excess risk with PPI therapy (risk ratio [RR]:
.22, 95% CI: 0.99 to 1.51) was progressively reduced with
dditional statistical analyses that controlled for confound-
ng variables and was considered inconclusive. Ray et al. (66)
tudied 20,596 Medicaid patients hospitalized for ACS or
evascularization. There was no cardiovascular risk during
ollow-up with PPI use (HR: 0.99; 95% CI: 0.82 to 1.19),
ut hospitalizations for gastroduodenal bleeding were 50%
ower than in nonusers. Charlot et al. (67) described
ncreased risk for PPI use regardless of clopidogrel use in
6,406 Danish patients, but no risk with individual PPIs. A
ecent meta-analysis (68) of 23 studies on clopidogrel–PPI
nteractions, many unpublished, further describes the limi-
ations of observational study design on accurately deter-
ining risk. Another meta-analysis concluded that patient
isk for cardiovascular events impacted PPI risk (69).
POST-HOC RANDOMIZED CLINICAL TRIAL REPORTS. Dunn
et al. (70) reported preliminary results in 366 patients from
the CREDO trial and found no difference in the 1-year risk
of death, stroke, or MI when PPI was added to clopidogrel.
O’Donoghue et al. (39) studied 13,608 patients in the
TRITON–TIMI 38 (Trial to Assess Improvement in Ther-
apeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis In Myocardial Infarction 38),
4,529 of whom were taking a PPI. No risk was found for the
composite end point of cardiovascular death, MI, or stroke
compared with the no PPI group (HR: 0.94, 95% CI: 0.80
to 1.11). Both studies showed higher risk for patients on
PPIs, suggesting that comorbidities, rather than a clopi-
dogrel–PPI interaction, may make patients higher risk for
adverse cardiac events.
RANDOMIZED CLINICAL TRIAL. The COGENT (Clopi-
ogrel and the Optimization of Gastrointestinal Events
rial) randomized 3,627 patients with ACS or PCI to a
xed-dose combination of controlled-release omeprazole 20
g–clopidogrel 75 mg/day or clopidogrel alone, but was
erminated early because of sponsor bankruptcy (71). Al-
hough underpowered, the secondary combined cardiovas-
ular end point of cardiovascular death, ischemic stroke,
onfatal MI, or revascularization was not different (HR:
.02, 95% CI: 0.70 to 1.51), but the composite primary
astrointestinal event rate was reduced with PPI use (HR:
.55, 95% CI: 0.36 to 0.85).
Clinical Studies That Evaluated the Coadministration of Clopidogrel and OmeprazoleTable 4 Clinical Studies That Evaluated the Coadministration of Clopidogrel and Omeprazole
First Author (Ref. #)
(Year) Design Population End Point n
Results, RR/OR/HR
(95% CI) Comments
Simon et al. (49)
(2009)
Retrospective registry cohort Acute MI Death, MI, stroke at 1 yr Omeprazole: 1,147
No PPI: 602
RR: 0.85 (0.69–1.05) No risk
Ho et al. (60)
(2009)
Retrospective administrative
database cohort
Hospital discharge
for ACS
Death or rehospitalization for
UA/MI at 17 months
Omeprazole: 3,132
No PPI: 2,961
OR: 1.24 (1.08–1.41) Increased risk in male veterans
O’Donoghue et al. (39)
(2009)
Retrospective RCT cohort ACS undergoing
PCI
CV death, MI, stroke at
15 months
Esomeprazole: 613
Lansoprazole: 441
Omeprazole: 1,675
Pantoprazole: 1,844
No PPI: 4,538
HR: 1.07 (0.75–1.52)
HR: 1.00 (0.63–1.59)
HR: 0.91 (0.72–1.15)
HR: 0.94 (0.74–1.18)
Risk associated with PPI use,
not coadministration
Rassen et al. (65)
(2009)
Retrospective administrative
database cohort
ACS or PCI Death, MI hospitalization at
30 days
Omeprazole; NA
Pantoprazole: NA
No PPI: NA
RR: 1.17 (0.68–2.01)
RR: 1.26 (0.93–1.71)
No risk
Low event rates
Ray et al. (66)
(2010)
Retrospective administrative
database cohort
UA, MI, PCI, CABG CV death, MI, stroke Esomeprazole: 690
Lansoprazole: 1,042
Omeprazole: 660
Pantoprazole: 4,349
No PPI: 13,003
HR: 0.71 (0.48–1.06)
HR: 1.06 (0.77–1.45)
HR: 0.79 (0.54–1.15)
HR: 1.08 (0.88–1.32)
No risk in Medicaid pts
Kreutz et al. (62)
(2010)
Retrospective administrative
database cohort
Stent implantation Hospitalization for CV death, ACS,
cerebrovascular event,
revascularization at 1 yr
Esomeprazole: 3,257
Lansoprazole: 785
Omeprazole: 2,307
Pantoprazole: 1,653
No PPI: 9,390
HR: 1.57 (1.40–1.76)
HR: 1.39 (1.16–1.67)
HR: 1.39 (1.22–1.57)
HR: 1.61 (1.41–1.88)
Increased risk for each PPI
Charlot et al. (67)
(2010)
Retrospective administrative
database cohort
30 days after MI CV death or rehospitalization for
MI or stroke
Esomeprazole: 5,316
Lansoprazole: 2,798
Omeprazole: 2,717
Pantoprazole: 4,698
No PPI: 40,764
Not quantitated Risk associated with PPI use,
not coadministration
CABG  coronary artery bypass graft; HR  hazard ratio; RR  risk ratio; other abbreviations as in Tables 1, 2, and 3.
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March 15, 2011:1251–63 Clopidogrel–Drug InteractionsIn summary, patients who receive PPIs are older and have
more comorbidity, making confounding and selection bias a
likely explanation for increased clinical risk in some obser-
vational studies. Whereas observational studies have pro-
duced discordant results for a clopidogrel–omeprazole in-
teraction, post hoc randomized clinical trial reports (39,70)
and 1 randomized clinical trial (71) have shown no signal for
increased cardiovascular risk with drug coadministration.
Other Clopidogrel–Drug Interactions
We initially demonstrated that CYP3A4 inhibitors (eryth-
romycin, troleandomycin, ketoconazole) decreased and
CYP3A4 inducers (rifampin) increased the antiplatelet
activity of clopidogrel (5,11). Several other clopidogrel–
drug interactions have subsequently been described (Fig. 1).
CYP inhibitors. Ketoconazole is a potent inhibitor of both
CYP3A4 and CYP3A5. Healthy subjects given loading and
maintenance doses of clopidogrel had decreased production
of active metabolite and significantly reduced platelet inhi-
bition on ketoconazole compared with control (72). Simi-
larly, the CYP3A inhibitor itraconazole significantly de-
creased the ability of clopidogrel to inhibit platelet
aggregation (73).
Dihydropyridine calcium channel blockers (nifedipine,
amlodipine) also inhibit CYP3A4. In observational studies,
they have been shown to decrease clopidogrel responsive-
ness as measured by the vasodilator-stimulated phosphopro-
tein (VASP) assay and electrical impedance aggregometry
(74) and by light transmission aggregometry and the
VerifyNow P2Y12 assay (Accumetrics, San Diego, Cali-
ornia) (75).
Phenprocoumon, an oral anticoagulant used in Europe, is
coumarin derivative metabolized by CYP3A4 and
YP2C9. Concomitant treatment with clopidogrel attenu-
ted the antiplatelet effect of clopidogrel and increased the
umber of nonresponders (76).
Cangrelor, an ATP analogue, is a parenteral reversible
2Y12 receptor inhibitor with a short half-life that results in
ormalization of platelet aggregation approximately 30 min
fter discontinuation of the infusion. When clopidogrel was
iven simultaneously with cangrelor and cangrelor was
ontinued for 2 h, there was no inhibition of the P2Y12
receptor by clopidogrel after the infusion was stopped
because the clopidogrel active metabolite was unavailable for
binding due to its short half-life (77). When clopidogrel was
started at the time the cangrelor infusion was discontinued,
there was inhibition of the P2Y12 receptor. Importantly, it
akes 2 to 4 h for clopidogrel to reach maximal effect.
herefore, there could be an important gap in platelet
nhibition while the patient transitions from cangrelor to
lopidogrel.
YP inducers. We initially demonstrated that clopidogrel
esponsiveness could be increased by coadministration with
ifampin, a CYP3A4 and CYP2C19 inducer, and that
onresponders could become responsive (5,11). Judge et al.78) have recently proven that this response is due to
ncreased production of the clopidogrel active metabolite
nd increased P2Y12 receptor blockade.
By inhibiting the platelet P2Y12 receptor, clopidogrel
increases intracellular cyclic adenosine monophosphate
(cAMP), a key signaling molecule in inhibiting platelet
aggregation. Caffeine also increases cAMP levels and has
been shown to enhance platelet inhibition by clopidogrel
(79). Other methylxanthines (theophylline) and phospho-
diesterase inhibitors (cilostazol) also increase platelet cAMP
levels (80).
Smoking is a known CYP1A2 inducer, and several
studies have demonstrated increased platelet inhibition (81),
fewer ischemic events (82,83), and increased bleeding risk
(83) in smokers following clopidogrel administration.
Omega-3 polyunsaturated fatty acids (PUFA) were shown
in 1 small prospective randomized trial to increase clopidogrel
responsiveness, but the mechanism is unclear (84).
St. John’s wort (Hypericum perforatum) is an herbal
product used to treat depression. It also induces CYP3A4
activity. In healthy volunteers who were nonresponders to
clopidogrel, St. John’s wort 300 mg thrice daily for 14 days
improved the platelet inhibitory activity of clopidogrel by
increasing CYP3A4 metabolic activity (85).
Confounding Variables in
the Drug Interaction Debate
There are many confounding variables that have contributed
to the discordant results regarding potential clopidogrel–
drug interactions:
1. Dose effect. Inhibition of clopidogrel activation by ator-
vastatin appears to be dose-dependent (5), consistent
with the hypothesis that atorvastatin is a competitive
inhibitor of CYP3A4. Studies with high loading doses of
clopidogrel (600 mg) and lower doses of atorvastatin (10
to 20 mg) could miss the inhibitory effect of high-dose
atorvastatin on a lower clopidogrel loading dose (17).
2. Time effect. Suboptimal production of active metabolite
following clopidogrel loading dose administration could
eventually be overcome as active metabolite production
eventually accumulates from maintenance dosing and
binds to initially unblocked platelet receptors. Moreover,
only 10% to 15% of the platelet pool is regenerated daily
and platelet reactivity decreases with time after the
initiating event, making it unlikely that a sustained
inhibition of platelet aggregation could be maintained by
a drug interaction. Additionally, 3 recent reports suggest
that the interaction between CYP2C19 polymorphisms
and the effect of clopidogrel on clinical events is limited
to a few weeks (86–88).
3. Class effect. Only clopidogrel interactions with a single
statin (atorvastatin) and a single PPI (omeprazole) ap-
pear to be important. Studies that evaluate clopidogrel–
statin and clopidogrel–PPI interactions miss the point
that these drug–drug interactions do not appear to be a
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dynamic differences between agents within a drug class.
. Clopidogrel response variability. Genetic, cellular, and
metabolic factors influence clopidogrel responsiveness
(89). Drug interactions may only be important in pa-
tients with borderline platelet inhibition, where small
reductions in platelet inhibition might result in post-
treatment platelet reactivity above therapeutic thresh-
olds. Additionally, alternative CYP isoenzyme pathways
may become more active in patients with concomitant
treatment of competing agents.
. Ex vivo platelet function testing. The role of platelets in
thrombosis is complex; platelet function tests on isolated
platelets measure only part of this process. Test hetero-
geneity, lack of standardization, operator dependency,
and lack of an accepted gold standard challenge the
accurate measurement of variable platelet reactivity.
. Offsetting clinical effects. Atorvastatin has a number of
beneficial pleiotropic effects (LDL reduction, decreased
inflammation, plaque stabilization, fibrinolysis stimula-
tion, improved endothelial function), including platelet
inhibition, associated with decreased MI and death rates
that could offset the negative clinical effect of any
potential reduction in platelet inhibition with clopi-
dogrel. Likewise, omeprazole reduces bleeding events,
linked to risk for acute and future ischemic events,
potentially neutralizing an adverse clinical effect on
platelet inhibition.
esearch Challenges in
he Drug Interaction Debate
here are many research challenges in scientifically measur-
ng the clinical importance of drug–drug interactions.
. Study design. Treatment in observational studies is based
on clinical need or physician preference, creating selec-
tion bias, so these studies can only suggest association,
not conclude causality. Claims-based studies are partic-
ularly limited by missing or misclassified data. Outcome
events in randomized trials are often adjudicated, but
multivariable or propensity score analyses in post hoc
studies cannot completely adjust for differences in un-
known or unmeasured confounders. Only a randomized
clinical trial could confirm the importance of a drug–
drug interaction at the population level, although the
generalizability of the results would be modified by
inclusion and exclusion criteria and the potential cost of
such a trial would probably be prohibitive.
. Sample size. The published studies have not been appro-
priately powered to address clopidogrel–drug interac-
tions. The absolute reduction in major adverse cardiac
events at 30 days when clopidogrel is added to aspirin
compared with aspirin monotherapy is only 1% (90),
making it possible that studies demonstrating no clopi-
dogrel–drug interactions were insufficiently powered to
detect a small, but clinically meaningful, difference inevent rates when millions of patients are prescribed these
drugs.
. Composite primary end point. Increased individual events
related to attenuation of platelet inhibition by a drug–
drug interaction (MI, transient ischemic attack) might be
neutralized by other events not mediated by platelet
aggregation (noncardiac death, target vessel revascular-
ization), producing a net effect that obscures a potential
drug interaction.
. Clinical risk. Only specific patient subgroups may have
clinical risk. Low CYP 3A4 metabolic activity,
CYP2C19 polymorphisms, age, sex, diabetes mellitus,
increased body mass index, and renal insufficiency also
decrease clopidogrel responsiveness. Drug–drug interac-
tions in subgroups of patients may not be recognized in
population analyses. Moreover, the small reduction in
platelet aggregation (10% to 15%) with clopidogrel–drug
interactions may not be clinically significant in many
subgroups.
. Patient compliance. A major obstacle to finding a clinical
clopidogrel–drug interaction is assuring patient compli-
ance with coadministration of both medications during
the study period. Measuring medication use at 1 point in
time does not assure continued use of both medications.
onclusions
here are many pharmacodynamic clopidogrel–drug inter-
ctions, but there is no consistent evidence that these
nteractions have clinical significance. Because the benefit of
ual antiplatelet therapy is well established and the existing
linical data on clopidogrel–drug interactions are inconclu-
ive, clinicians should concentrate on initiating proper statin
herapy in patients with coronary artery disease and pre-
cribing PPIs for patients at increased risk for gastroduode-
al bleeding. The therapeutic benefit of coadministering
hese medications to appropriate patients should greatly
xceed any theoretical harm from clopidogrel–drug inter-
ctions that appear to be dose-dependent, time-dependent,
nd mild compared with the larger challenges of patient
ompliance and interindividual variability in clopidogrel
esponsiveness. Clinicians concerned about these interac-
ions have the option of prescribing a different platelet
2Y12 receptor inhibitor without known drug interactions
(39,72,91). Another option is to prescribe a hydrophilic
statin in place of atorvastatin; or pantoprazole or ranitidine,
an H2RA not metabolized by CYP isoenzymes, in place of
omeprazole (92).
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